Finanzen von Palvella Therapeutics Inc (PVLA)PVLAPalvella Therapeutics Inc

Evaluating the bottom line, Palvella Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.63%, provide a clear picture of how effectively PVLA converts its operational activities into shareholder value.

In the context of the broader market, PVLA competes directly with industry leaders such as LKFT and ALMR. With a market capitalization of $2.00B, it holds a leading position in the sector. When comparing efficiency, PVLA's gross margin of N/A stands against LKFT's 25.00% and ALMR's 60.21%. Such benchmarking helps identify whether Palvella Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Palvella has reported consistent losses, with a net income loss of $21.87 million projected for Q2 2026 and an EPS of -1.52 for the last quarter, missing expectations by $0.34. The current ratio is strong at 21.18, indicating good short-term liquidity, but the overall financial outlook remains concerning due to ongoing losses.